From Defining Bioinformatics and Pharmacogenomics to Developing Information-Based Medicine and Pharmacotyping in Health Care

Handbook of Pharmaceutical Biotechnology

Volumn , Issue , 2006, Pages 201-228

  Vizirianakis, Ioannis S ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Cancer pharmacogenomics and pharmacotyping; Defining bioinformatics and pharmacogenomics; Information based platform development

Indexed keywords

EID: 34548837046     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470117118.ch2     Document Type: Chapter

References (115)

1. Evans W E, McLeod H L (2003). Pharmacogenomics-drug disposition, drug targets, and side effects. N. Engl. J. Med. 348:538-549.
2. Pirmohamed M, Park B K (2001). Genetic susceptibility to adverse drug reactions. Trends Pharmacol. Sci. 22:298-305.
3. Müller M (2003). Pharmacogenomics and the complexity of drug response. Int. J. Clin. Pharmacol. Ther. 41:231-240.
4. Ginsburg G S, McCarthy J J (2001). Personalized medicine: Revolutionizing drug discovery and patient care. Trends Biotechnol. 19:491-496.
5. Vizirianakis I S (2005). Improving pharmacotherapy outcomes by pharmacogenomics: From expectation to reality? Pharmacogenomics, In Press.
6. Housman D, Ledley F D (1998). Why pharmacogenomics? Why now? Nature Biotechnol. 16:2-3.
7. Evans W E, Relling M V (1999). Pharmacogenomics: Translating functional genomics into rational therapeutics. Science. 286:487-491.
8. McLeod H L, Evans W E (2001). Pharmacogenomics: Unlocking the human genome for better drug therapy. Annu. Rev. Pharmacol. Toxicol. 41;101-121.
9. Roses A D (2000). Pharmacogenetics and the practice of medicine. Nature. 405: 857-865.
10. Vizirianakis I S (2004). Challenges in current drug delivery from the potential application of pharmacogenomics and personalized medicine in clinical practice. Curr. Drug Deliv. 1:73-80.
11. Nebert D W, Nebert L J, Vesell E S (2003). Pharmacogenomics and "individualized drug therapy": High expectations and disappointing achievements. Am. J. Pharmacogenomics. 3:361-370.
12. Lazarou J, Pomeranz B H, Corey P N (1998). Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies. J. Am. Med. Assoc. 279:1200-1205.
13. Kohn L T, Corrigan J M, Donaldson M S (Eds.) (2000). To Err is human: Building a safer health system. Committee on Quality of Health Care in America. Institute of Medicine, The National Academy Press, Washington, D.C.
14. Flockhart D A, Tanus-Santos J E (2002). Implications of cytochrome P450 interactions when prescribing medication for hypertension. Arch. Intern. Med. 162:405-412.
15. Ingelman-Sundberg M (2004). Pharmacogenetics of cytochrome P450 and its applications in drug therapy: The past, present and future. Trends Pharmacol. Sci. 25: 193-200.
16. Ebbesen J, Buajordet I, Erikssen J, et al. (2001). Drug-related deaths in a department of internal medicine. Arch. Intern. Med. 161:2317-2323.
17. Ingelman-Saundberg M, Oscarson M, McLellan R A (1999). Polymorphic human cytochrome P450 enzymes: An opportunity for individualized drug treatment. Trends Pharmacol. Sci. 20:342-349.
18. Meyer U A (2000). Pharmacogenetics and adverse drug reactions. Lancet. 356:1667-1671.
19. Furuta T, Shirai N, Sugimoto M, et al. (2004). Pharmacogenomics of proton pump inhibitors. Pharmacogenomics. 5:181-202.
20. Schwab M, Eichelbaum M, Fromm M F (2003). Genetic polymorphisms of the human MDR1 drug transporter. Annu. Rev. Pharmacol. Toxicol. 43:285-307.
21. Siddiqui A, Kerb R, Weale M E, et al. (2003). Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N. Engl. J. Med. 348:1442-1448.
22. Guillemette C (2003) Pharmacogenomics of human UDP-glucuronosyltransferase enzymes. Pharmacogenomics J. 3:136-158.
23. Hetherington S, Hughes A R, Mosteller M, et al. (2002). Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet. 359:1121-1122.
24. Mallal S, Nolan D, Witt C, et al. (2002). Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet. 359:727-732.
25. Vizirianakis I S (2006). The transformation of pharmacogenetics into pharmacogenomics reinforces personalized medicine towards pharmacotyping for improved patient care. In Barnes L P (ed.), New Research on Pharmacogenetics: Nova Science Publishers, Inc., New York., In Press.
26. Watters J W, McLeod H L (2003). Cancer pharmacogenomics: Current and future applications. Biochim. Biophys. Acta. 1603:99-111.
27. Meisel P (2002). Arylamine N-acetyltransferases and drug response. Pharmacogenomics. 3:349-366.
28. Anantharam A, Markowitz S M, Abbott G W (2003). Pharmacogenetic considerations in diseases of cardiac ion channels. J. Pharmacol. Exp. Ther. 307:831-838.
29. Tsai Y J, Hoyme H E (2002). Pharmacogenomics: The future of drug therapy. Clin. Genet. 62:257-264.
30. McLeod H L, Siva C (2002). The thiopurine S-methyltransferase gene locus- implications for clinical pharmacogenomics. Pharmacogenomics. 3:89-98.
31. Coulthard S A, Hall A G (2001). Recent advances in the pharmacogenomics of thiopurine methyltransferase. Pharmacogenomics J. 1:254-261.
32. Arranz M J, Munro J, Birkett J, et al. (2000). Pharmacogenetic prediction of clozapine response. Lancet. 355:1615-1616.
33. Cadman P E, O'Connor D T (2003). Pharmacogenomics of hypertension. Curr. Opin. Nephrol. Hypertens. 12:61-70.
34. Manasco P K, Rieser P, Renegar G (2002). Pharmacogenetics and the genetic basis of ADRs. In: Mann, R D, Andrews, E B (eds.), Pharmacovigilance: Wiley, West Sussex, pp. 516-553.
35. Small K M, Tanguay D A, Nandabalan K, et al. (2003). Gene and protein domainspecific patterns of genetic variability within the G-protein coupled receptor superfamily. Am. J. Pharmacogenomics. 3:65-71.
36. Drysdale C M, McGraw D W, Stack C B, et al. (2000). Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc. Natl. Acad. Sci. U.S.A. 97:10483-10488.
37. Shafran A, Ifergan I, Bram E, et al. (2005). ABCG2 harboring the Gly482 mutation confers high-level resistance to various hydrophilic antifolates. Cancer Res. 65:8414-8422.
38. Loktionov A (2004). Common gene polymorphisms, cancer progression and prognosis. Cancer Let. 208:1-33.
39. Anderson J L, Carlquist J F, Horne B D, et al. (2003). Cardiovascular pharmacogenomics: Current status, future prospects. J. Cardiovasc. Pharmacol. Ther. 8:71-83.
40. Cacabelos R (2004). The application of functional genomics to Alzheimer's disease. Pharmacogenomics. 4:597-621.
41. Ulrich C M, Robien K, Mcleod H L (2003). Cancer pharmacogenetics: Polymorphisms, pathways and beyond. Nat. Rev. Cancer. 3:912-920.
42. Sayers I, Hall I P (2005). Pharmacogenetic approaches in the treatment of asthma. Curr. Allergy Asthma Rep. 5:101-108.
43. Rusnak J M, Kisabeth R M, Herbert D P, et al. (2001). Pharmacogenomics: A clinician's primer on emerging technologies for improved patient care. Mayo Clin. Proc. 76:299-309.
44. McCarthy J J, Hilfiker R (2000). The use of single-nucleotide polymorphism in pharmacogenomics. Nature Biotechnol. 18:505-508.
45. Carpenter A E, Sabatini D M (2004). Systematic genome-wide screens of gene function. Nature Rev. Genet. 5:11-22.
46. Rudnicki M, Mayer G (2003). Pharmacogenomics of angiotensin converting enzyme inhibitors in renal disease-pathophysiological considerations. Pharmacogenomics. 4:153-162.
47. Humma L M, Terra S G (2002). Pharmacogenetics and cardiovascular disease: Impact on drug response and applications to disease management. Am. J. Health-Syst. Pharm. 59:1241-1252.
48. Ferrari P, Bianchi G (2000). The genomics of cardiovascular disorders. Drugs. 59:1025-1042.
49. Nakagawa K, Ishizaki T (2000). Therapeutic relevance of pharmacogenetic factors in cardiovascular medicine. Pharmacol. Ther. 86:1-28.
50. Ferrari P (1998). Pharmacogenomics: A new approach to individual therapy of hypertension? Curr. Opin. Nephrol. Hypertens. 7:217-222.
51. Liew C-C, Dzau V J (2004). Molecular genetics and genomics of heart failure. Nat. Rev. Genet. 5:811-825.
52. Roberts R, Brugada R (2003). Genetics and arrhythmias. Annu. Rev. Med. 54:257-267.
53. Saavedra J M (2005). Studies on genes and hypertension: A daunting task. J. Hypertension. 23:929-932.
54. Kurland L, Lind L, Melhus H (2005). Using genotyping to predict responses to antihypertensive treatment. Trends Pharmacol. Sci. 26:443-447.
55. Wrighton S A, Schuetz E G, Thummel K E, et al. (2000). The human CYP3A subfamily: Practical considerations. Drug Metab. Rev. 32:339-361.
56. Nelson D R, Zeldin D C, Hoffman S M, et al. (2004). Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics. 14:1-18.
57. Phillips K A, Veenstra D L, Oren E, et al. (2001). Potential role of pharmacogenomics in reducing adverse drug reactions: A systematic review. J. Am. Med. Assoc. 286:2270-2279.
58. Kirchheiner J, Brosen K, Dahl M L, et al. (2001). CYP2D6 and CYP2C19 genotypebased dose recommendations for antidepressants: A first step towards subpopulationspecific dosages. Acta Psychiatr. Scand. 104:173-192.
59. Gabelli C (2003). Rivastigmine: An update on therapeutic efficacy in Alzheimer's disease and other conditions. Curr. Med. Res. Opin. 19:69-82.
60. Bentue-Ferrer D, Tribut O, Polard E, et al. (2003). Clinically significant drug interactions with cholinesterase inhibitors: A guide for neurologists. CNS Drugs. 17:947-963.
61. Sadee W, Hoeg E, Lukas J, et al. (2001). Genetic variations in human G proteincoupled receptors: Implications for drug therapy. AAPS PharmSci. 3(3):E22. Available: http://www.pharmsci.org.
62. Desta Z, Zhao X, Shin J-G, et al. (2002). Clinical significance of the cytochrome P4502C19 genetic polymorphism. Clin. Pharmacokinet. 41:913-958.
63. Sakaeda T, Nakamura T, Okumura K (2003). Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs. Pharmacogenomics. 4:397-410.
64. Bredel M, Zentner J (2002). Brain-tumour drug resistance: The bare essentials. Lancet Oncol. 3:397-406.
65. Hall I P (2002). Pharmacogenetics, pharmacogenomics and airway disease. Respir. Res. 3:10.
66. Watters J W, McLeod H L (2003). Cancer pharmacogenomics: Current and future applications. Biochim. Biophys. Acta. 1603:99-111.
67. McLeod H L, Watters J W (2004). Irinotecan pharmacogenetics: Is it time to intervene? J. Clin. Oncol. 22:1356-1359.
68. Krynetski E Y, Evans W E (2000). Genetic polymorphism of thiopurine Smethyltransferase: Molecular mechanisms and clinical importance. Pharmacology. 61: 136-146.
69. O'Kane D J, Weinshilboum R M, Moyer T P (2003). Pharmacogenomics and reducing the frequency of adverse drug events. Pharmacogenomics. 4:1-4.
70. Marshall E (2003). Preventing toxicity with a gene test. Science. 302:588-590.
71. Coulthard S A, Hogarth L A, Little M, et al. (2002). The effect of thiopurine methyltransferase expression on sensitivity to thiopurine drugs. Mol. Pharmacol. 62:102-109.
72. Goldstein D B (2003). Pharmacogenetics in the laboratory and the clinic. N. Engl. J. Med. 348:553-556.
73. Traxler P (2003). Tyrosine kinases as targets in cancer therapy-successes and failures. Expert Opin. Ther. Targets. 7:215-234.
74. Tenen D G (2003). Disruption of differentiation in human cancer: AML shows the way. Nature Rev. Cancer. 3:89-101.
75. Graf T (2002). Differentiation plasticity of hematopoietic cells. Blood. 99:3089-3101.
76. Hockenbery D M, Giedt C D, O'Neill J W, et al. (2002). Mitochondria and apoptosis: New therapeutic targets. Adv. Cancer Res. 85:203-242.
77. Fischer O M, Streit S, Hart S, et al. (2003). Beyond Herceptin and Gleevec. Curr. Opin. Chem. Biol. 7:490-495.
78. Tsiftsoglou A S, Pappas I S, Vizirianakis I S (2003). Mechanisms involved in the induced differentiation of leukemia cells. Pharmacol Ther. 100:257-290.
79. Capdeville R, Buchdunger E, Zimmermann J, et al. (2002). Clivec (STI-571, imatinib), a rationally developed, targeted anticancer drug. Nature Rev. Drug Discov. 1:493-502.
80. Cowan-Jacob S W, Guez V, Fendrich G, et al. (2004). Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment. Mini Rev. Med. Chem. 4:285-299.
81. Suzuki T, Mitsudomi T, Hida T (2004). The impact of EGFR mutations on gefitinib sensitivity in non-small cell lung cancer. Personalized Med. 1:27-34.
82. Golsteyn R M (2004). The story of gefitinib, an EGFR kinase that works in lung cancer. Drug Discov. Today. 9:587.
83. Paez J G, Janne P A, Lee J C, et al. (2004). EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science. 304:1497-1500.
84. Lynch T J, Bell D W, Sordella R, et al. (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350:2129-2139.
85. Golsteyn R M (2005). Gefitinib does not increase survival in lung cancer patients. Drug Discov. Today. 10:381.
86. Domen J (2001). The role of apoptosis in regulating hematopoietic stem cell numbers. Apoptosis. 6:239-252.
87. Tsiftsoglou A S, Pappas I S, Vizirianakis I S (2003). The developmental program of murine erythroleukemia cells. Oncol. Res. 13:339-346.
88. Lindpaintner K (2002). The impact of pharmacogenetics and pharmacoge-nomics on drug discovery. Nature Rev. Drug Discov. 1:463-469.
89. Cho H-S, Mason K, Ramyar K X, et al. (2003). Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature. 421:756-760.
90. Ma X J, Salunga R, Tuggle J T, et al. (2003). Gene expression profiles of human breast cancer progression. Proc. Natl. Acad. Sci. U.S.A. 100:5974-5979.
91. Minn A J, Gupta G P, Siegel P M, et al. (2005). Genes that mediate breast cancer metastasis to lung. Nature. 436:518-524.
92. Cheok M H, Yang W, Pui C H, et al. (2003). Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells. Nature Genet. 34:85-90.
93. Slonim D K (2001). Transcriptional profiling in cancer: The path to clinical pharmacogenomics. Pharmacogenomics. 2:123-136.
94. Vizirianakis I S (2002). Pharmaceutical education in the wake of genomic technologies for drug development and personalized medicine. Eur. J. Pharm. Sci. 15:243-250.
95. Gurwitz D, Weizman A, Rehavi M (2003). Education: Teaching pharmacogenomics to prepare future physicians and researchers for personalized medicine. Trends Pharmacol. Sci. 24:122-125.
96. Brock T P, Valgus J M, Smith S R, et al. (2003). Pharmacogenomics: Implications and considerations for pharmacists. Pharmacogenomics. 4:321-330.
97. Wieczorek S J, Tsongalis G J (2001). Pharmacogenomics: Will it change the field of medicine? Clin. Chim. Acta. 308:1-8.
98. Hughes I, Hollingsworth M, Jones S J, et al. (1997). Knowledge and skills needs of pharmacology graduates in first employment: How do pharmacology courses measure up? Trends Pharmacol. Sci. 18:111-116.
99. Landro J A, Taylor I C, Stirtan W G, et al. (2000). HTS in the new millennium: The role of pharmacology and flexibility. J. Pharmacol. Toxicol. Methods. 44:273-289.
100. Rodriguez R, Vidrio H, Lopez-Martinez E, et al. (1997). Changing the countenance of pharmacology courses in medical schools. Trends Pharmacol. Sci. 18:314-318.
101. Varmus H (2002). Getting ready for gene-based medicine. N. Engl. J. Med. 347:1526-1527.
102. Tate S K, Goldstein D B (2004). Will tomorrow's medicines work for everyone? Nat. Genet. 36:S34-S42.
103. Lindpaintner K (2002). The impact of pharmacogenetics and pharmacoge nomics on drug discovery. Nature Rev. Drug Discov. 1:463-469.
104. Issa A M (2000). Ethical considerations in clinical pharmacogenomics research. Trends Pharmacol. Sci. 21:247-250.
105. Issa A M (2002). Ethical perspectives on pharmacogenomic profiling in the drug development process. Nat. Rev. Drug Discov. 1:300-308.
106. Weber W W, Caldwell M D, Kurth J H (2003). Edging toward personalized medicine. Curr. Pharmacogenomics. 1:193-202.
107. Debouck C, Goodfellow P N (1999). DNA microarrays in drug discovery and development. Nature Genet. 21(Suppl):48-50.
108. Sander C (2000). Genomic medicine and the future of health care. Science. 287: 1977-1978.
109. Schmitz G, Aslanidis C, Lackner K J (2001). Pharmacogenomics: Implications for laboratory medicine. Clin. Chim. Acta. 308:43-53.
110. Hardiman G (2004). Microarray platforms-comparisons and contrasts. Pharmacogenomics. 5:487-502.
111. Ekins S (2004). Predicting undesirable drug interactions with promiscuous proteins in silico. Drug Discov. Today. 9:276-285.
112. Gardner S P (2005). Ontologies and semantic data integration. Drug Discov. Today. 10:1001-1007.
113. Gage B F, Eby C, Milligan P E, et al. (2004). Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb. Haemost. 91:87-94.
114. Voora D, McLeod H L, Eby C, et al. (2005). The pharmacogenetics of coumarin therapy. Pharmacogenomics. 6:503-513.
115. Hall I P (2005). Pharmacogenetics and ethnicity: More complexities of personalized prescribing. Am. J. Respir. Crit. Care Med. 171:535-536.